Efficient Assistance, YITU AI assists with Epidemic Prevention and Control of COVID-19 Outbreak

Food and Healthcare Press Releases Tuesday March 17, 2020 10:51
SHANGHAI--17 Mar--PRNewswire/InfoQuest

According to its official public account of Shanghai Public Health Clinical Center, one of the authoritative institutions in the field of infectious diseases in China and the key unit for the treatment of COVID-19 in Shanghai, an article titled "AI Aids the Scientific Prevention and Control, Intelligent Evaluation System for COVID-19 Launched in Shanghai Public Health Clinical Center", announced its latest achievements in using artificial intelligence technology to help doctors carry out quantitative analysis and evaluation of therapeutic efficacy of new coronavirus lesions based on CT images.

YITU Healthcare reinforced its R&D capability with multi-departments cooperation right after the outbreak of the pandemic and released its cutting-edge AI diagnosis system, with upgrades on a daily basis during the Chinese New Year. YITU assisted many designated medical institutions and supported the frontline heroes fighting the pandemic.

The Intelligent Evaluation System of Chest CT for COVID-19, developed by YITU under the guidance of Shanghai Public Health Clinical Center, was officially launched and was put into the first-line battle against COVID-19 pandemic on 28th Jan. It is the first AI-equipped diagnostic assistant, which significantly improves efficiency in identifying coronavirus through automatic detection and quantitative analysis within 2-3 seconds, and eases the burden of Chinese doctors.

COVID-19 Diagnosis and Treatment Plan (Trial Version 7) issued by the General Office of the National Health Commission of the People's Republic of China stipulates that CT imaging results should be used as one of the criteria for the diagnosis of COVID-19 nationwide. At the same time, based on clinical experience, the CT imaging performance of COVID-19 is further clarified and the quantitative evaluation of CT images is incorporated into the clinical classification basis.

YITU's AI-driven solution of intelligent diagnosis and quantitative evaluation of CT images of COVID-19, are through industry-leading image algorithms, and grade the severity of various pneumonia diseases of local lesions, diffuse lesions, and whole lung involvement. Furthermore, it accurately quantifies the cumulative pneumonia load of the disease through quantitative and omics analysis of key image features such as the morphology, range, and density of the lesion, and achieves a dynamic 4D contrast of the lung lesions on the CT, helping in clinical judgment of the condition, evaluation of the efficacy, and prediction of the prognosis.

Taking up the challenge and responsibility in response to frontline needs and requests, YITU's Intelligent Evaluation System of Chest CT for COVID-19 has been adopted across 25 provinces and municipal autonomous prefectures in 100 medical institutions and served over 100,000 person-times in China by far.

For more information contact: Yiru, +86-21-5255-9588

Latest Press Release

Ansell Urges Global Priority For Supply Of Personal Protective Equipment

Ansell Limited, a global leader in protective solutions, is working with governments and health organizations worldwide to ensure unrestricted personal protective equipment (PPE) manufacture and supply is given top priority during the COVID-19...

Yiling Pharmacy Lianhua Qingwen has been approved by the Thai FDA

On March 31, Shijiazhuang Yiling Pharmaceutical Co., Ltd released a notice that they had received the approval of the modern herbal medicine registration issued by the Food and Drug Administration of Thailand. Lianhua Qingwen Capsule is recognized as in...

EW Nutrition Launches Industry-leading Webinar Series With Topical Antimicrobial Resistance Twin Sessions

Yesterday, German-based company EW Nutrition took a first step toward serving the animal production industry in these challenging times. The in-feed and on-farm solutions company has started a series of topical webinars on challenging issues such as...

Saxenda(R) Demonstrated Improvements in BMI and Body Weight in Adolescents With Obesity

Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda(R) (liraglutide 3.0 mg) in adolescents (aged 12–<18) with obesity.1 The study was accepted...

Johnson & Johnson Announces a Lead Vaccine Candidate for COVID-19; Landmark New Partnership with U.S. Department of Health & Human Services; and Commitment to Supply One Billion Vaccines Worldwide for Emergency Pandemic Use

Johnson & Johnson and BARDA Together Commit More than $1 Billion to Novel Coronavirus Vaccine Research and Development; Company Expects to Initiate Phase 1 Human Clinical Studies of Vaccine Candidate at Latest by September 2020 Johnson & Johnson...

Related Topics